Quality measurement for soft tissue sarcomas in Germany – first results of the Certified Sarcoma Centres
Conclusions: A sarcoma-specific quality assurance scheme that includes guideline-derived quality indicators was developed. In future, a broader database will allow further insights into sarcoma care in Germany. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 31, 2023 Category: Cancer & Oncology Source Type: research
Changes In Tumor Immune Microenvironment After Radiotherapy Resistance In Colorectal Cancer: a Narrative Review
Background: Colorectal cancer (CRC) is a common digestive tract malignancy with high incidence and mortality rates. Radiotherapy is the most common anti-tumor therapeutic regime and is frequently used for treating CRC, especially rectal cancer. However, radiotherapy can lead to tumor resistance to treatment. While previous research on radiotherapy resistance in CRC has mostly focused on the tumor itself, recent advances, especially the emergence of immunotherapy, have led to a greater emphasis on the immune microenvironment of the tumor.
Summary: This review summarizes the recent literature on the role of the tumor immune...
Source: Oncology Research and Treatment - March 22, 2023 Category: Cancer & Oncology Source Type: research
Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation
Conclusion: Given the durable response observed, olaparib can be a valuable therapeutic tool in BRCA-mutant CCAs. Ongoing and future clinical trials are needed to confirm the role of PARP inhibition in similar patients and to define the clinicopathological and molecular profile of the individuals most likely to benefit. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 7, 2023 Category: Cancer & Oncology Source Type: research
Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation
Conclusion: Given the durable response observed, olaparib can be a valuable therapeutic tool in BRCA-mutant CCAs. Ongoing and future clinical trials are needed to confirm the role of PARP inhibition in similar patients and to define the clinicopathologic and molecular profile of the individuals most likely to benefit. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 7, 2023 Category: Cancer & Oncology Source Type: research
Association between Resting Heart Rate and Oncological Outcomes in Patients with Early-Stage Cervical Cancer Who Have Undergone Radical Hysterectomy with Pelvic Lymphadenectomy
Conclusion: This is the first study to demonstrate that RHR may be an independent prognostic factor for oncological outcomes in patients with CC. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 6, 2023 Category: Cancer & Oncology Source Type: research
Association between resting heart rate and oncological outcomes in patients with early-stage cervical cancer who have undergone radical hysterectomy with pelvic lymphadenectomy
Conclusion: This is the first study to demonstrate that RHR may be an independent prognostic factor for oncological outcomes in patients with CC. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 6, 2023 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2023;46:126 –130 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 3, 2023 Category: Cancer & Oncology Source Type: research
Melflufen: Therapieoptionen beim Multiplen Myelom
Oncol Res Treat 2023;46:125 –125 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - March 3, 2023 Category: Cancer & Oncology Source Type: research
High In-Hospital Mortality in SARS-CoV-2-Infected Patients with Active Cancer Disease during Omicron Phase of the Pandemic: Insights from the CORONA Germany Study
Conclusion: The CORONA Germany study indicates that hospitalized patients with active cancer disease are at high risk of death during a SARS-CoV-2 infection. Mortality of patients with history of cancer improved to nearly the level of non-cancer patients during Omicron phase. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 23, 2023 Category: Cancer & Oncology Source Type: research
High in-hospital mortality in SARS-CoV-2 infected patients with active cancer disease during Omicron phase of the pandemic – Insights from the CORONA Germany Study
Conclusion:
The CORONA Germany study indicates that hospitalized patients with active cancer disease are at high risk of death during a SARS-CoV-2 infection. Mortality of patients with history of cancer improved to nearly the level of non-cancer patients during Omicron phase. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 23, 2023 Category: Cancer & Oncology Source Type: research
Patterns of care and survival in cancer patients with brain metastases receiving immune checkpoint inhibitors
Conclusion: Long-term survival is possible in patients managed with ICI ± brain-directed treatment. This study did not identify a clear treatment sequence of choice. MDT assessment at diagnosis and each progression is recommended to ensure favorable outcomes. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 15, 2023 Category: Cancer & Oncology Source Type: research
